World news and discussion on TalkFuse.
New Chinese weight-loss drug produces bigger results than Wegovy in under a year
A 48-week trial found that the experimental Chinese drug ribupatide helped participants lose an average of up to 17.7% of their starting weight. The results put it in a similar range to, or above, those reported for Wegovy in a separate, longer trial, though the studies cannot be directly compared.
Researchers at Fudan University studied 567 adults with overweight or obesity, who received one of three weekly ribupatide doses or a placebo alongside diet and exercise advice. Weight loss ranged from 10.7% at the lowest dose to 17.7% at the highest, and the higher-dose groups had not yet reached a plateau. Participants also saw improvements in blood sugar, blood pressure and cholesterol; common side effects included nausea, vomiting and diarrhoea. Hengrui is developing the drug with US biotech firm Kailera Therapeutics for markets outside China.
In short
- Ribupatide users lost up to 17.7% of their weight in 48 weeks.
- The trial involved 567 adults and three weekly dose levels.
- Digestive side effects were common, while several health measures improved.